An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550
Latest Information Update: 23 Jun 2022
At a glance
- Drugs INCB 086550 (Primary) ; INCB 086550 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Incyte Corporation
- 16 Jun 2022 Status changed from recruiting to completed.
- 28 Mar 2022 Planned primary completion date changed from 14 Mar 2022 to 12 May 2022.
- 28 Mar 2022 Status changed from active, no longer recruiting to recruiting.